Beam Therapeutics to Present Data Highlighting Robust Manufacturing Process for BEAM-101 at 2024 European Hematology Association (EHA) Hybrid Congress
May 14 2024 - 4:00PM
Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company
developing precision genetic medicines through base editing, today
announced that the company will report data highlighting the
robust, closed and automated manufacturing process for BEAM-101, as
deployed in the BEACON Phase 1/2 clinical trial, in a poster
presentation at the European Hematology Association (EHA) Hybrid
Congress, hosted virtually and in person in Madrid, Spain on June
13-16, 2024.
Abstract details are listed below and available online on the
EHA meeting library website.
Title: Robust autologous CD34+ HSPC
manufacturing with a closed and automated process optimized for
patients with sickle cell diseasePoster Session Date and
Time: Friday, June 14, 2024, 6:00 p.m.
CESTAbstract: P1479Presenting
Author: Paul Kopesky, Ph.D., vice president, process
development at Beam Therapeutics
About BEAM-101BEAM-101 is an investigational
genetically modified cell therapy for the treatment of sickle cell
disease (SCD). The one-time therapy consists of autologous CD34+
hematopoietic stem and progenitor cells (HSPCs) that have been
base-edited in the promotor regions of the HBG1/2 genes and are
administered via a hematopoietic stem cell transplant procedure.
The BEAM-101 edit is designed to inhibit the transcriptional
repressor BCL11A from binding to the promoter without disrupting
BCL11A expression, leading to increased production of non-sickling
and anti-sickling fetal hemoglobin (HbF) and thus mimicking the
effects of naturally occurring variants seen in hereditary
persistence of fetal hemoglobin. HbF is the predominant hemoglobin
variant during development and early life. The safety and efficacy
of BEAM-101 is being evaluated in the ongoing BEACON Phase 1/2
study, an open-label, single-arm, multicenter trial in adult
patients with SCD.
About Beam TherapeuticsBeam Therapeutics
(Nasdaq: BEAM) is a biotechnology company committed to establishing
the leading, fully integrated platform for precision genetic
medicines. To achieve this vision, Beam has assembled a platform
that includes a suite of gene editing and delivery technologies and
is in the process of building internal manufacturing capabilities.
Beam’s suite of gene editing technologies is anchored by base
editing, a proprietary technology that is designed to enable
precise, predictable and efficient single base changes, at targeted
genomic sequences, without making double-stranded breaks in the
DNA. This has the potential to enable a wide range of potential
therapeutic editing strategies that Beam is using to advance a
diversified portfolio of base editing programs. Beam is a
values-driven organization committed to its people, cutting-edge
science, and a vision of providing life-long cures to patients
suffering from serious diseases.
Cautionary Note Regarding Forward-Looking
StatementsThis press release contains forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Investors are cautioned not to place undue
reliance on these forward-looking statements, including, but not
limited to, statements related to: the therapeutic applications and
potential of our technology, including with respect to sickle cell
disease; our plans, and anticipated timing, to advance our BEAM-101
program; the clinical trial designs and expectations for BEAM-101;
and our ability to develop life-long, curative, precision genetic
medicines for patients through base editing. Each forward-looking
statement is subject to important risks and uncertainties that
could cause actual results to differ materially from those
expressed or implied in such statement, including, without
limitation, risks and uncertainties related to: our ability to
successfully achieve the benefits of our portfolio prioritization
and strategic restructuring; our ability to develop, obtain
regulatory approval for, and commercialize our product candidates,
which may take longer or cost more than planned; our ability to
raise additional funding, which may not be available; the
uncertainty that our product candidates will receive regulatory
approval necessary to initiate human clinical studies; that
preclinical testing of our product candidates and preliminary or
interim data from preclinical studies and clinical trials may not
be predictive of the results or success of ongoing or later
clinical trials; that initiation and enrollment of, and anticipated
timing to advance, our clinical trials may take longer than
expected; that our product candidates may experience manufacturing
or supply interruptions or failures; risks related to competitive
products; and the other risks and uncertainties identified under
the headings “Risk Factors Summary” and “Risk Factors” in our
Annual Report on Form 10-K for the year ended December 31, 2023,
our Quarterly Report on Form 10-Q for the quarter ended March 31,
2024, and in any subsequent filings with the Securities and
Exchange Commission. These forward-looking statements speak only as
of the date of this press release. Factors or events that could
cause our actual results to differ may emerge from time to time,
and it is not possible for us to predict all of them. We undertake
no obligation to update any forward-looking statement, whether as a
result of new information, future developments or otherwise, except
as may be required by applicable law.
Contacts:
Investors:Holly ManningTHRUST Strategic
Communicationsholly@thrustsc.com
Media:Dan Budwick1ABdan@1abmedia.com
Beam Therapeutics (NASDAQ:BEAM)
Historical Stock Chart
From May 2024 to May 2024
Beam Therapeutics (NASDAQ:BEAM)
Historical Stock Chart
From May 2023 to May 2024